Clinical Talks: From BMC to Wall Street
September 9 @ 09:00 – 09:30 CEST
After our recent planning hiatus, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting, innovative, and enlightening season. This season will focus on sustainable innovations within Life Sciences, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations.
Season 5, will be held September until December 2021 with a total of seven scheduled Talks, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
Dr. Andrea Ballagi, Olink Proteomics VP Sales and Marketing
Andrea Ballagi has an MD from Semmelweis School of Medicine in Budapest, a PhD in Cancer research from Ludwig Institute for Cancer Research in Uppsala and a MBA from Uppsala University. She started her industry career at IDEXX Laboratories located in Switzerland as a general manager and later moved back to Uppsala as a global technical service and product line manager in 2011. Andrea joined Olink in 2012 as director of commercial operations and has since been a major part of the company’s expansive growth phases. She currently serves as VP Sales and Marketing EMEA.
Andrea has with her roots as an MD a real passion to change the way diagnostics is being conducted to in today’s clinical reality. By bringing in groundbreaking technological possibilities and unprecedented future treatment options made possible by the extensive Olink technological platform.
Dr. Simon Fredriksson, Co-Founder Olink
Simon Fredriksson has a PhD in Molecular Medicine from Uppsala University and conducted postdoctoral studies in biochemistry at Stanford University, and most recently appointed Adjunct Professor at KTH. He is also the co-founder of Olink, and both former CSO, and CEO of the company in its formation and growth phases. His academic research resulted in multiple high impact publications and inventions that were commercialized into products. Most notably the Proximity-Ligation and -Extension assays for multiplex protein detection, the main products of Olink Proteomics.
In 2015, Simon co-founded and was the former CEO of Genagon Therapeutics, a ground-breaking immuno-oncology company. Presently co-founder and CEO of Pixelgen Technologies, and Partner in Colibri Ventures, a premier life science business incubator, that helps start-ups develop early ideas into successful companies faster and more efficient. Simon also has extensive board member experience from 9 years at Olink AB (partly exited to Nexttobe 2011), Biolamina AB (+6 years), Olink Proteomics AB (exited to Summa Equity 2019), and Cartana AB (exited to 10X Genomics 2020) and Genagon Therapeutics.
As an experienced life science entrepreneur, researcher and inventor spanning from research tools to bio-therapeutics, Simon has always been fascinated by technology innovation capable of pushing the frontiers of scientific discovery into new and unchartered territories.